An observational study in Urothelial Carcinoma, Diagnoses Disease and Ureter Cancer, sponsored by Changhai Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.
Sponsored by Changhai Hospital · Observational
Upper tract urothelial carcinoma (UTUC) diagnosis include urography using computed tomography urography (CTU) or urography using MRI (MRU). The sensitivity of CTU decreases substan¬tially with decreasing lesion size. Other drawbacks of CTU include the radiation exposure and potential adverse effects in patients with allergic reactions or pre-existing renal impairment. In terms of urine cytology, the major drawbacks of urine cytology are low sensitivity and highly dependent of the experience and skills of the cytopathologist. We here intended to investigate whether UroCAD can be added in the diagnostic work-up of UTUC patient, and improve the accuracy of predicting UTUC before surgery.
The recommendations for imaging in UTUC diagnosis include urography using CTU or MRU. In the standard diag¬nostic work up, urine cytology and a cystoscopy to rule out a concomitant bladder tumor are also advised. In addition, diagnostic ureterorenoscopy and biopsy are advised in patients in whom the findings of these pro¬cedures could influence treatment decisions, The sensitivity of CTU decreases substan¬tially with decreasing lesion size. For polypoid tumors of 5-10 mm maximal diameter, CTU has a high sensitivity and specificity, but sensitivity decreases to 89% for lesions \<5 mm and further to 40% for lesions \<3 mm. Flat lesions are even more difficult to diagnose. Other drawbacks of CTU include the radiation exposure and the need for intravenous contrast media with accompa¬nying potential adverse effects in patients with allergic reactions or pre-existing renal impairment. In terms of urine cytology, the major drawbacks of urine cytology tests: the sensitivity of positive urine cytology is highly dependent on tumor grade and decreases to 12% for low-grade tumors and 15% for non-invasive stage Ta tumors. Hence, low-grade urothelial tumors cannot be reliably detected by urine cytology. Finally, the accuracy of the cytology findings is highly dependent of the experience and skills of the cytopathologist. Our previous study has proved that UroCAD, which is able to detect chromosomal aberrations of the urine exfoliated cells, is a reliable method in diagnosing urothelial carcinoma with sensitivity and specificity of 82.5% and 96.9%, respectively. But its potential role in diagnosis of UTUC in combination with CTU and cytology hasn't been assessed yet and the accuracy of UroCAD in detecting UTUC still need to be further validated. We here intended to investigate whether UroCAD can be added in the diagnostic work-up of UTUC patient, and improve the accuracy of predicting UTUC before surgery.
119 studies on the registry are indexed under Ureteral Neoplasms; 19 are open to participants now.
This study's planned enrollment of 110 is below the median of 735 across 16 observational studies indexed under Ureteral Neoplasms.
Browse Ureteral Neoplasms studies →Changhai Hospital is the lead sponsor of 342 studies on the registry; 133 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients suspected of UTUC or participants in control group from September 2021 to October 2022 in Changhai hospital
Patients suspected with UTUC and planned to undergo surgery such as such ureteroscopy or radical nephroureterectomy.
Participants without any tumor disease and willing to attend the study by providing morning urine.
Male or female patients aged >= 18 years. Participants signed informed consent form.
Exclusion Criteria:
Individuals unwilling to sign the consent form or unwilling to provide morning urine for test or unwilling to provide the medical record.
Patient already received suprapubic cystostomy or urethral catheterization. Participants with late-stage uremia and need regular dialysis. Participants with reasons like elevated serum creatinine, allergy to intravenous CT contrast media et al, and unable to undergo CTU.
Patient with cancer other than urothelial carcinoma.
The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice (N=80).
Diagnostic Test: UroCAD assay, CTU examination and urine cytology
Patients need to undergo CTU examination and being treated for benign diseases with ureteroscopy, but without any tumor will provide a negative control to provide data for determining the sensitivity and specificity of UroCAD, CTU and cytology assay (N=30).
Diagnostic Test: UroCAD assay, CTU examination and urine cytology
The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
Sensitivity and Specificity of urinalysis by UroCAD assay combined with CTU and cytology
Number of patients "declared positive" with the UroCAD assay, CTU or cytology among the patients suffered from UTUC and number of patients "declared negative" with these tests among the patients without cancer.
Time frame: Through study completion, an average of 30 months
Identification of the correlation between the level of CNV and the grade of the tumor sample
Level of CNV in the urine sample compared with the grade of the tumor confirmed by histopathologic examination
Time frame: Through study completion, an average of 30 months
Identification of the correlation between the level of CNV and the stage of the tumor sample
Level of CNV in the urine sample compared with the stage of the tumor confirmed by histopathologic examination
Time frame: Through study completion, an average of 30 months
Comparison of the sensitivity and specificity of the UroCAD analysis versus urine cytology and CTU
Number of patients "declared positive" with the UroCAD analysis versus patients "declared positive" with the urine cytology or CTU, and number of patients "declared negative" with the UroCAD analysis versus patients " declared negative " with the urine cytology or CTU.
Time frame: Through study completion, an average of 30 months
Plan to share: No — To pretect the personal privacy of participants and the genetic sequencing information, IPD data will not be shared.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changhai Hospital